AI & life science: what’s next
Artificial intelligence is redefining what is possible in Life Science. The theme “AI & Life Science: What’s Next?” explores the latest breakthroughs, key challenges, and future opportunities in AI-driven healthcare and biotechnology. This year’s theme highlights how rapidly evolving AI technologies are transforming every stage of the life science ecosystem. From research and diagnostics to drug development and patient care, this virtual conference brings together Swedish and American perspectives to discuss how innovation is shaping the next era of Life Science.
WHAT IS LIFE SCIENCE BRIDGE?
The Life Science Bridge is a joint initiative between the regional Swedish-American Chambers of Commerce in San Diego, San Francisco/Silicon Valley, New England, and Minnesota. The initiative supports life science companies by offering market insights, networking opportunities, and events that foster connections, collaboration, and knowledge exchange between Sweden and the leading U.S. life science ecosystems.
The Swedish American Chamber of Commerce is a non-profit organization with the mission of facilitating and supporting trade, commerce, and investment between the U.S. and Sweden.
Meet the Speakers
Dr. Krishna P. Allamneni is an experienced biopharmaceutical executive and strategic advisor with more than 25 years of expertise in early drug development and corporate strategy. She currently serves as Chief Development Officer and Executive Vice President at Concarlo Therapeutics and Senior Advisor at Ventures Accelerated AB, guiding therapeutics from discovery to commercialization across multiple therapeutic areas and modalities.
Throughout her career, Krishna has contributed to 25+ Investigational New Drug (IND) applications and seven marketed products, driving growth and innovation by aligning scientific discovery with business strategy and regulatory pathways. Her leadership has spanned major biopharma companies including Turning Point Therapeutics (now BMS), Jazz Pharmaceuticals, Genentech/Roche, and Celera Genomics, as well as advisory and mentoring roles with leading life science incubators.
Erik Hemberg, is a research scientist at MIT CSAIL specializing in artificial intelligence and data-driven methods across life sciences, cybersecurity, and complex systems. With over 15 years of experience in AI, machine learning, and data science, his work bridges cutting-edge computational techniques with real-world applications in neuroscience, learning systems, and biomedical and security domains.
He has collaborated with leading organizations including OpenAI, MIT-IBM AI Alliance, DARPA, MIT Lincoln Laboratory, and U.S. government agencies, securing competitive research funding for interdisciplinary AI initiatives.
Marek Szczygiel M.D., leads the team through insight shaped by his blend of medical expertise and technology based innovation at Anyo Labs. He received his medical degree at Poznan University of Medical Sciences and MSc. in Entrepreneurship and Business Design at Chalmers University of Technology. Anyo Labs is a biotech company that uses artificial intelligence and advanced computational modeling to help pharmaceutical and biotech organizations discover and design new medicines faster and more efficiently. By virtually screening and optimizing millions of potential compounds, the company accelerates the early stages of drug development and reduces reliance on time-consuming traditional lab processes.
Wing Cheng is a seasoned executive and board professional with deep expertise in the life science and medtech sectors. Wing is currently senior business developer, Life Science at Uppsala Innovation Center supporting innovative start-ups in Region Uppsala. In parallel he serves as a board professional in Life Science companies including chairman in LanteRNA. He is also a mentor in the elite Nordic Mentor Network for Entrepreneurship (NOME), supporting high-potential life science startups. His executive experience also includes leadership roles at Immuneed, Biovica, Thermo Fisher Scientific, and Cepheid AB, covering business development, market access, and regulatory strategy. His operational background also spans co-founding and leading Strike Pharma.
Earlier in his career, Wing was an expert at the Swedish Medical Products Agency and represented Sweden in key EU bodies such as the European Medicines Agency’s Committee for Advanced Therapies and the European Commission’s Medical Device Expert Group. He also held roles at TLV, where he assessed HTA applications and contributed to reimbursement policy at national and EU levels. Wing holds a Ph.D. from Uppsala University and brings a unique blend of regulatory, entrepreneurial, and governance expertise.